Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is This an Obesity-Drug Success or Failure?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Arena Pharmaceuticals (NASDAQ: ARNA  ) and VIVUS (NASDAQ: VVUS  ) are the two stocks most typically associated with obesity drugs, but diabetes-drug maker Novo Nordisk (NYSE: NVO  ) is also trying to enter this space. The company is completing phase 3 clinical trials in an attempt to get Victoza approved as a weight-loss drug for obese and overweight patients with type 2 diabetes.

After reporting data from a clinical study today, shares of Novo Nordisk fell almost 5%. In the following video, health-care analyst Max Macaluso discusses what this news means for investors and how this drug fits into the obesity-drug market.

Who will win the obesity-drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2319065, ~/Articles/ArticleHandler.aspx, 9/27/2016 3:29:54 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,214.47 119.64 0.66%
S&P 500 2,158.77 12.67 0.59%
NASD 5,300.88 43.39 0.83%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 3:14 PM
ARNA $1.80 Up +0.07 +4.05%
Arena Pharmaceutic… CAPS Rating: ***
AZN $33.56 Up +0.01 +0.03%
AstraZeneca CAPS Rating: ****
BMY $55.59 Up +0.11 +0.20%
Bristol-Myers Squi… CAPS Rating: ****
NVO $43.79 Down -0.64 -1.44%
Novo Nordisk CAPS Rating: *****
VVUS $1.19 Down -0.05 -4.03%
VIVUS CAPS Rating: **